2023 World Conference on Lung Cancer (Posters)-P2.05. Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1

P2.05. Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1 - PDF(Abstract)

Back to course

Pdf Summary

The study presented at the WCLC 2023 conference focused on the analysis of T-cell infiltration in patients with advanced non-small cell lung cancer (NSCLC) who received canakinumab in combination with standard of care treatment. Canakinumab is an inhibitor of IL-1β, which is recognized as an important pro-inflammatory cytokine in cancer progression. The primary endpoints of the study, which included progression-free survival (PFS) and overall survival (OS), were not met, and no significant difference in clinical response was observed across predefined biomarker subgroups. However, the analysis of CD8 tumor-infiltrating lymphocytes, which play a crucial role in antitumor immune responses, showed that high T-cell infiltration status was associated with improved OS and PFS, regardless of treatment arm. In patients with a low total CD8 count, canakinumab treatment demonstrated a trend towards improved median OS and improved median PFS compared with placebo. In patients with an immune desert T-cell phenotype, median PFS improved compared with placebo, while median OS was not reached in the canakinumab arm. The transcriptome analysis revealed that patients with low CD8 counts and immune desert phenotype had higher suppressive myeloid tumor microenvironment features. Based on preclinical studies and a neoadjuvant trial, the combination of canakinumab and immune checkpoint inhibitors has shown promise in decreasing immunosuppressive features and activating a CD8-driven antitumor response. Further clinical validation is needed to confirm these findings and evaluate the potential benefit of canakinumab in patients with low T-cell infiltration.

Asset Subtitle

Daniel Tan

Meta Tag

Speaker Daniel Tan

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

T-cell infiltration

non-small cell lung cancer

canakinumab

IL-1β inhibitor

progression-free survival

overall survival

CD8 tumor-infiltrating lymphocytes

antitumor immune responses

immune desert phenotype

myeloid tumor microenvironment